Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: Preparation, characterization and pharmacokinetics

Journal of Controlled Release

Volumn 76, Issue 1-2, 2001, Pages 107-117

  Dosio, Franco ^a   Arpicco, Silvia ^a   Brusa, Paola ^a   Stella, Barbara ^a   Cattel, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Albumin; Antitumoral agent; Macromolecular drug conjugate; Paclitaxel; Poly(ethylene glycol)

Indexed keywords

ANTINEOPLASTIC AGENT; HUMAN SERUM ALBUMIN PACLITAXEL CONJUGATE; PACLITAXEL; POLY(ETHYLENE GLYCOL) 2000 HUMAN SERUM ALBUMIN PACLITAXEL CONJUGATE; POLY(ETHYLENE GLYCOL) 5000 HUMAN SERUM ALBUMIN PACLITAXEL CONJUGATE; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL STRAIN HT29; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; INTERNALIZATION; MELANOMA; MELANOMA CELL; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RADIOACTIVITY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; PACLITAXEL; POLYETHYLENE GLYCOLS; SERUM ALBUMIN;

EID: 0035845748     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(01)00420-5     Document Type: Article

References (35)

1. The current state of adjuvant therapy for breast cancer: Focus on paclitaxel
2. The current role and future prospects of paclitaxel in the treatment of small cell lung cancer
3. Weekly paclitaxel in the management of ovarian cancer
4. A new parenteral emulsion for the administration of taxol
5. Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system
6. A submicron lipid emulsion coated with amphipatic polyethylene glycol for parenteral administration of paclitaxel (taxol)
7. Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol
8. Novel taxol formulations: Preparation and characterization of taxol-containing liposomes
9. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes
10. Preparation, characterization and properties in vitro and in vivo of liposomes containing water-soluble prodrugs of paclitaxel
11. Development of amphiphilic diblock copolymers as micellar carrier of taxol
12. Determination of a new polymer-bound paclitaxel derivative (PNU 166945), free paclitaxel and 7-epipaclitaxel in dog plasma and urine by reversed-phase high-performance liquid chromatography with UV detection
13. Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate
14. Final report on the safety assessment of polyethylene glycols (PEGs)-6, -8, -32, -75, -150, -14M, -20M
15. Polyethylene glycol
16. Immunotherapy with monomethoxypolyethylene glycol modified allergens
17. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weight after intravenous administration in mice
18. The uses and properties of PEG-linked proteins
19. The conjugation of proteins with polyethylene glycol and other polymers: Altering properties of protein to enhance their therapeutic potential
20. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation
21. Use of functionalized polyethylene glycols for modification of polipeptides
22. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): A water-soluble prodrug
23. Drug delivery systems: Water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness
24. Synthesis, characterization and properties of new poly(ethyleneglycol) derivatives
25. The chemistry of imidates
26. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid
27. Stabilization of substances in circulation
28. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates
29. New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability
30. Toxin-targeted design for anticancer therapy. I: Preparation and biological comparison of different chemically linked gelonin-antibody conjugates
31. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins
32. Pharmacokinetic properties of polyethylene glycol derivatized superoxide dismutase
33. Plasma clearance and immunologic properties of long-acting superoxide dismutase prepared using 35 000 to 120 000 dalton poly-ethylene glycol
34. Prolongation of the serum half-life period of superoxide dimutase by poly(ethylene glycol) modification